One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART StudyCamilla Muccini, Antonella Castagna, Tommaso Clemente et al.|Open Forum Infectious Diseases|2024Cited by 20
In-depth Analysis of the HIV Reservoir Confirms Effectiveness and Safety of Dolutegravir/Lamivudine in a Phase 4 Randomized Controlled Switch Trial (RUMBA)Marie‐Angélique De Scheerder, Linos Vandekerckhove, Camilla Muccini et al.|The Journal of Infectious Diseases|2024Cited by 8
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemicRebecka Papaioannu Borjesson, Vincenzo Spagnuolo, Tommaso Clemente et al.|Frontiers in Medicine|2023Cited by 4
Outcomes after a virological failure to first-line second-generation INSTI-based therapy in a real-life settingRebecka Papaioannu Borjesson, Vincenzo Spagnuolo, Camilla Muccini et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 2
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registryTommaso Clemente, Flavia Balena, Antonio Di Biagio et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 2